tada

Excellent point re AZ. Any BP or others could jump into this. This could lead to competitive bidding between the BPs.

Passing the FA could really add fuel to this fire.

Also, the failure of CEPT inhibtors and their underlying theory should steer pharma development to seek new approaches such as epigenetics. 

Apabetalone has at least demonstrated promise based on the post hoc findings and all of the follow up analysis on the MOA and discovering the multimodal impact in 6 key systems.

RVX has 1500 plus compunds that they have tested to some level.

So if the underlying epigenetic theory shows progress, which it has, BP could jump in.

GLTA

Toinv

Toinv